Related Experiment Video
Updated: Aug 8, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease
Mario Hero1,2, Nadja Grozdanić1, Romana Brnić Andrić1
1Clinic of Neurology, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Movement Disorders Clinical Practice
|August 7, 2026
Summary
Continuous subcutaneous levodopa-carbidopa prodrugs (LDp/CDp) improved motor function and quality of life in advanced Parkinson's disease patients over one year. This therapy led to increased levodopa equivalent dosage and decreased dopamine agonist use.
Area of Science:
- Neurology
- Pharmacology
- Clinical Medicine
Background:
- Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) offers 24-hour levodopa-carbidopa delivery for advanced Parkinson's disease.
- Limited real-world 1-year data exist for LDp/CDp in European populations.
Purpose of the Study:
- To assess 1-year changes in motor, non-motor, autonomic, and quality-of-life outcomes with LDp/CDp.
- To evaluate changes in concomitant therapies during 1 year of LDp/CDp treatment.
Main Methods:
- Retrospective, single-center observational study.
- Involved 32 patients initiated on LDp/CDp between April 2024 and January 2026.
- Follow-up data collected at 1 year.
Main Results:
- 62.5% of patients completed 1-year follow-up.
- Significant improvements observed in MDS-UPDRS Part III (motor), Part IV (motor fluctuations), and Part II (ADLs).
- Quality of life improved; non-motor and autonomic symptoms remained unchanged. Levodopa-equivalent dose increased by 31.7%, while oral dopamine agonist use decreased significantly.
Conclusions:
- One year of LDp/CDp treatment is associated with significant motor benefits and improved quality of life in advanced Parkinson's disease.
- The observed benefits were achieved with an increased levodopa equivalent dose and a reduction in dopamine agonist use.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...